Our ecosystem is stuck in a cycle of blame that benefits no one. Sponsors point to poor site performance, while sites point to overly complex protocols from sponsors. And regulators blame both of them. The result is a cycle where everyone waits for someone else to fix what is broken. This culture of division is more damaging than any single setback. The finger-pointing is a massive operational drag; it creates friction, burns out investigators, and ultimately stalls the very progress we all claim to want.
The system is already under strain. Rising costs, complex protocols, and pressure to deliver faster results make clinical trials harder than ever. Patients see delays in new treatments. Researchers lose trust in the process. When blame dominates, collaboration suffers, and without collaboration there can be no progress.
A protocol designed in a silo is a blueprint for failure. When we don’t engage clinical sites and patients in the design process, we create studies that are operationally unworkable and completely misaligned with the patient’s real-world experience. We are missing significant clinical trial opportunities not because the science is flawed, but because the logistics were never tested against reality.
The most critical shift we need to make is from transactional handoffs to shared ownership of outcomes. This isn’t about being nicer; it’s about restructuring partnerships so that sponsors, CROs, and sites share the risks and the rewards of a trial’s success or failure. When everyone has skin in the game, a problem for one becomes a problem for all to solve.
When we argue over whose process is broken, the only stakeholder who consistently loses is the patient. Every delay caused by internal friction or a splintered system is a delay in getting a potentially life-altering therapy to the people waiting for it. Reframing our mission around the patient is the fastest way to drive meaningful clinical trial collaboration.
Real progress will not come from demanding that another group fix their part of the system first. It will come when we bring our collective expertise to the table to solve shared problems, creating forums where sites can give honest feedback without reprisal and sponsors can co-design with the people who will actually run the trial. We have to stop trying to perfect our own piece and start working to fortify the whole chain.
Building Strength Through Clinical Trial Collaboration
True progress in research depends on unity. Clinical trials involve many moving parts: sponsors, investigators, regulators, and patients. Each group brings essential expertise, but when they operate in silos, efforts overlap, and resources are wasted. Collaboration breaks down those walls. It creates a single team focused on one outcome: better care for patients.
Practical steps toward clinical trial collaboration include shared planning sessions, transparent communication, and aligned goals from the start of a study. These efforts ensure everyone understands challenges and can address them together. Importantly, they foster trust. Trust turns conflict into cooperation and criticism into constructive feedback.
There are strong examples of this approach in action. Multisite trials using centralised data platforms allow real-time sharing of updates, reducing delays and miscommunication. Advisory boards that include both patients and clinicians ensure protocols reflect real-world realities rather than theoretical ideals. This shift towards partnership supports faster enrolment and better retention while improving study quality. The message is simple. When people share responsibility, trials move forward. When they focus on blame, trials stall.
Recognising the Hidden Cost of Blame
Blame is easy, but it comes with hidden costs. Every delay caused by finger-pointing means a patient somewhere is waiting longer for a potential treatment. Every mistrust between teams means more duplicated effort and wasted resources. Over time, these costs add up to stalled innovation and lost opportunities to save lives.
This mindset also discourages new players from entering the field. Small research sites or emerging biotech companies often struggle to navigate partnerships because they fear being scapegoated when problems arise. The result is a less diverse ecosystem, with fewer voices contributing to the search for better therapies.
Breaking this cycle starts with shifting attitudes. Instead of asking “Who is at fault?” we must ask “What can we do together to fix this?” That single change turns frustration into action. It also reinforces the principle that everyone in research shares the same ultimate goal: better outcomes for patients.
Unlocking Growth Through Clinical Trial Opportunities
Amid the challenges, there are also significant clinical trial opportunities. The demand for clinical research is growing as new therapies emerge across oncology, neurology, rare diseases, and more. Yet many opportunities remain untapped because of the fragmentation in the system. Coordinated approaches can unlock these opportunities and open doors for innovation.
Investing in technology is one part of the solution. Shared digital platforms for patient data, remote monitoring, and electronic consent reduce administrative burdens and improve trial efficiency. But technology alone is not enough. Teams must be willing to work together and share insights to get the most from these tools.
Partnerships with community organisations can also expand access to trials in underserved areas. By building trust with local healthcare providers and patients, researchers can increase enrolment and ensure trials better reflect real-world populations. When stakeholders stop competing for credit and start collaborating on solutions, they create a research environment where innovation can flourish.
Practical Steps to Reduce Friction
Turning ideals into action requires practical steps. The first is communication. Clear, consistent updates between sponsors, investigators, and regulatory bodies minimise misunderstandings and allow problems to be addressed quickly. The second is shared accountability. Establishing joint goals and metrics ensures no single party bears all the blame when challenges arise. The third is patient inclusion. Involving patients early in trial design not only improves retention but also highlights potential problems before they escalate.
Another crucial factor is culture. Teams that celebrate small wins and learn from setbacks together foster resilience. This mindset encourages continuous improvement rather than finger-pointing. It also makes clinical research more attractive to new talent, strengthening the entire field.
Training programmes can reinforce these principles. Equipping staff with skills in conflict resolution, negotiation, and inclusive leadership helps prevent small disagreements from spiralling into major disputes. Over time, these skills contribute to a healthier, more productive research environment.
When combined, these practical changes shift the focus from blame to progress. They transform trials from fractured processes into cohesive partnerships where everyone works toward a shared mission.
Researchers, sponsors, and patients all have a stake in fixing the system. Progress will not come from waiting for others to act. It will come from recognising our shared responsibility and choosing collaboration over criticism.
Progress continues when everyone works together. Let’s speak about practical steps to take toward clinical trial collaboration.
Keith Berelowitz | Founder & CEO
Keith Berelowitz is the Founder of pRxEngage, a company redefining patient engagement and retention in clinical trials using living experience, proven methods, and AI.
